Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

GRHU, ACOR, ENDP, ZION, - Stock Report!

|Includes:Acorda Therapeutics, Inc. (ACOR), ENDP, ZION



grhu_logo_200x72 GreenHouse Holdings, Inc. (OTCQB:GRHU) is a San Diego, California based integrator of some of the world’s most innovative environmental, public safety, infrastructure technologies.

GRHU previously announced that PepsiCo(NYSE:R) will partner with GreenHouse to utilize Southern California Edison’s (SCE) Automated Demand Response (Auto-DR) program at its Buena Park bottling plant. GreenHouse is a qualified service provider of SCE’s Auto-DR program, providing site assessment, feasibility studies, project development, engineering, installation of enabling technologies and complete processing of all incentives.

In addition, GreenHouse Holdings, Inc. recently reported the signing of a Letter of Intent to acquire Control Engineering, Inc (CEI). The acquisition, when consummated, is expected to significantly increase gross margins in GreenHouse’s Energy Services Division via vertical integration of CEI’s business. The acquisition is also expected to provide cross-selling opportunities of GreenHouse products and services to CEI’s existing clients.

For more information about this company please visit


Acorda Therapeutics, Inc. (NASDAQ:ACOR) reported Monday November 1, 2010 that it rebounded to a profit in the third quarter due to increasing sales of its new multiple sclerosis drug Ampyra. For the period ended Sept. 30, the company reported net income of $12.4 million, or 31 cents per share, compared with a net loss of $19.4 million, or 51 cents per share, in the same period of 2009. Excluding one-time events, analysts expected earnings per share of 12 cents, on average.

Acorda Therapeutics, Inc., a biotechnology company, develops therapies for multiple sclerosis, spinal cord injury, and other nervous system disorders.


Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) third-quarter net income climbed as branded drug sales improved. The pharmaceutical company, which has been on an acquisition spree, also gave a 2011 adjusted earnings outlook above Wall Street’s expectations. Earnings for the three months ended Sept. 30 rose 10 percent to $54.2 million, or 46 cents per share. A year earlier, net income was $49.4 million, or 42 cents per share.

Endo Pharmaceuticals Holdings Inc., through its subsidiary, Endo Pharmaceuticals Inc., engages in the research, development, manufacture, marketing, and sale of branded and generic prescription pharmaceuticals in the United States.


Zions Bancorp. (NASDAQ:ZION) announced that its board of directors declared a regular quarterly dividend of $0.01 per common share. The dividend is payable November 23, 2010 to shareholders of record on November 10, 2010. The board of directors also declared the regular quarterly cash dividends on the company’s various perpetual preferred shares. The cash dividend on the Series A, C, and E shares are payable on December 15, 2010 to shareholders of record on December 1, 2010.

Zions Bancorporation is one of the nation’s premier financial services companies, consisting of a collection of great banks in select high growth markets. Zions operates its banking businesses under local management teams and community identities through approximately 500 offices in 10 Western and Southwestern states: Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah and Washington.





Sign-Up For Free Stock Alerts At


business Card 3



Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received ten thousand dollars in cash and anticipates another ten thousand dollars in cash from the company for 60 days of advertisement services for Green House Holdings, Inc. (GRHU). In addition to the cash, Crown Equity Holdings Inc. (OTCPK:CRWE) also anticipates receiving 20,000 shares of 144 restricted stocks from a third party. .